Reviews
Type-III interferons in Sjögren’s syndrome
E. Apostolou1, A.G. Tzioufas2
- Department of Pathophysiology, and Academic Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Greece.
- Department of Pathophysiology, and Academic Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Greece. agtzi@med.uoa.gr
CER13536
2020 Vol.38, N°4 ,Suppl.126
PI 0245, PF 0252
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 32896259 [PubMed]
Received: 08/05/2020
Accepted : 01/06/2020
In Press: 02/09/2020
Published: 23/10/2020
Abstract
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterised by aberrant activation of innate and adaptive immune responses. Part of this hyper-activation is due to the interferon (IFN) system. Deregulated expression and activity of the type-I IFN system has been extensively studied in pSS. Type-III interferons (IFNs) are the latest addition to the IFN family, and exhibit potent anti-viral functions, similarly to type-I IFNs. More recently they have started to attract attention as key modulators in the interface of innate and adaptive immunity and chronic inflammation. Deregulated expression of type-III IFNs has been demonstrated in various autoimmune diseases over the last ten years. The scope of this review is to summarise recent findings regarding the biology of type-III IFNs in pSS. We highlight factors that regulate their induction, their downstream effects, their similarities and differences with type-I IFNs and their possible modes of action in Sjögren’s syndrome. Finally, we discuss their potential benefits as targets for therapeutic intervention.
